The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or without Insulin Resistance

Sacchinelli, Angela; Venturella, Roberta; Lico, Daniela; Cello, Annalisa Di; Lucia, Antonella; Rania, Erika; Cirillo, Roberto; Zullo, Fulvio

doi:10.1155/2014/141020

Cited by 18 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] Recently, supplementation with myo-inosiol and N-acetyl-cysteine has been demonstrated to ameliorate the metabolic profile of PCOS patients, also improving clinical characteristics, ovarian function, and hormonal parameters. [1,9,10] …”

Section: Hirsutism and Menstrual Disordersmentioning

confidence: 99%

Will emerging pharmacotherapies improve the management of polycystic ovarian syndrome?

Rocca

Venturella

Mocciaro

et al. 2016

Expert Opinion on Emerging Drugs

Self Cite

View full text Add to dashboard Cite

Section: Hirsutism and Menstrual Disordersmentioning

confidence: 99%

Will emerging pharmacotherapies improve the management of polycystic ovarian syndrome?

Rocca

Venturella

Mocciaro

et al. 2016

Expert Opinion on Emerging Drugs

Self Cite

View full text Add to dashboard Cite

“…Inositol has attracted the attention of the food and feed industry, mainly used as an additive for drink, milk powder for nutrition supplement, and animal feed to prevent disease [7][8]. As a drug adulterant, inositol has been proved to treat some diseases such as diabetes and fatty liver [9][10][11]. Furthermore, inositol is an important intermediate used for the production of uronic acid and inositol derivative.…”

Section: Introductionmentioning

confidence: 99%

Efficient production of myo-inositol in Escherichia coli through metabolic engineering

You

Wang

Shi

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The biosynthesis of high value-added compounds through metabolically engineered strains has received widely attention in recent years. As an effective compound in pharmaceutical, cosmetic and food industry, myo-inositol (inositol) is mainly produced via a harsh set of chemical reactions from phytate. The proper distribution of carbon flux between cell growth and inositol production was a major challenge for constructing an efficient inositol-synthetic pathway. Recombinant E. coli strains have been constructed by metabolic engineering strategies to produce inositol, yet with a low yield. Therefore, construction of E. coli metabolically engineered strains with high stoichiometric yield will be attractive. Results In the present study, the recombinant E. coli strains with high stoichiometric yield (> 0.7 mol inositol/mol glucose) were obtained to efficiently synthesize inositol. Inositol was successfully biosynthesized after introducing two crucial enzymes, inositol-3-phosphate synthase (IPS) from Trypanosoma brucei , and inositol monophosphatase (IMP) from E. coli. Based on starting strains E. coli BW25113 (wild type) and SG104 ( ΔptsG::glk , ΔgalR::zglf , ΔpoxB::acs ), a series of engineered strains for inositol production were constructed by deleting the key genes pgi, pfkA or pykF . Furthermore, the plasmid expression systems of IPS and IMP were optimized, and the gene zwf was regulated to enhance stoichiometric yield. The highest stoichiometric yield (0.96 mol inositol/mol glucose) was achieved with the combined strain R15 of SG104, Δpgi , Δpgm , and RBSL5-zwf. Simultaneously, the engineered strain R04 reached high-density fermentation level in a 1-L fermenter by using glucose and glycerol as mixed carbon source. In the scale-up bioconversion in situ with R04, 0.82 mol inositol/mol glucose was produced by fed-batch within 23 h, corresponding to a titer of 106.3 g/L (590.5 mM). Conclusions The biosynthetic pathway of inositol from glucose in recombinant E. coli was optimized by metabolic engineering strategies. The metabolically engineered E. coli strains represent a promising method for future inositol production. This study provided an essential reference to obtain a suitable distribution of carbon flux between glycolysis pathway and product synthetic pathway.

show abstract

“…This medication has antioxidant properties and reduces insulin resistance (3)(4)(5). Since insulinresistance and hyperinsulinemia are the common causes of hyperandrogenism and anovulation, any agent that can reduce the insulin resistance can be beneficial in the treatment of infertility caused by PCOS (6).…”

Section: Introductionmentioning

confidence: 99%

Comparison of Pregnancy Rate in Patients With Polycystic Ovary Syndrome Treated With Clomiphene Alone and in Combination With N-acetyl Cysteine: A Randomized Clinical Trial

Ghomian

Khadem

Moeindarbari

et al. 2018

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

Objectives: Polycystic ovary syndrome (PCOS) is one of the frequent endocrine disorders among young females, which can cause infertility. Recently, evidence has shown the beneficial impacts of N-acetyl cysteine (NAC) use along with clomiphene citrate on the treatment of infertility caused by PCOS. Regarding this, the present study aimed to compare the pregnancy rate between the PCOS patients treated with clomiphene and those received clomiphene along with NAC. Materials and Methods: This blinded randomized controlled clinical trial was performed on 66 patients with PCOS who presented with infertility at Milad Infertility Center in Mashhad, Iran, in 2015. The patients were divided into two groups of intervention and control using a random number table. In the intervention group, 100 mg of clomiphene (i.e. two pills) along with 1200 mg of NAC (i.e. two 600 mg pills) were given to the participants from the third day of the menstrual cycle for five days. In the control group, 100 mg of clomiphene was administered from the third day of the cycle for 5 days. The patients’ response to medications as well as the number and size of follicles were assessed using the vaginal ultrasound. Results: The 2 study groups had no significant difference regarding age, duration of infertility, body mass index, history of infertility treatment, and endometrial thickness on the third day of the menstrual cycle. The mean endometrial thickness was 7.47±1.6 (NAC/ clomiphene) and 7.58±2.1 mm (clomiphene) on the 12th day of the menstrual cycle (P=0.810). Furthermore, the mean sizes of the follicles were 13.6±4.2 (clomiphene) and 15.9±5.1 mm (NAC/clomiphene) (P=0.301). The mean numbers of follicles were 1.56±0.9 (clomiphene) and 1.8±0.9 (NAC/clomiphene) (P=0.069). In total, 7 (21.2%) and 5 (15.1%) patients in the intervention and control groups had a positive beta-hCG result, respectively (P=0.260). Conclusions: As the findings of this study revealed, the addition of NAC to clomiphene treatment was not associated with an increased chance of pregnancy in patients with PCOS-related infertility.

show abstract

The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or without Insulin Resistance

Cited by 18 publications

References 11 publications

Will emerging pharmacotherapies improve the management of polycystic ovarian syndrome?

Will emerging pharmacotherapies improve the management of polycystic ovarian syndrome?

Efficient production of myo-inositol in Escherichia coli through metabolic engineering

Comparison of Pregnancy Rate in Patients With Polycystic Ovary Syndrome Treated With Clomiphene Alone and in Combination With N-acetyl Cysteine: A Randomized Clinical Trial

Contact Info

Product

Resources

About